Actelion Bets on Do-It-Yourself as Competition Lifts Drug Prices

Actelion Bets on Do-It-Yourself as Competition Lifts Drug Prices

Actelion Pharmaceuticals Ltd/copyright 2011 via Bloomberg

Actelion Ltd.'s lung medicine Tracleer is seen in this undated handout photograph. Diversifying is important because Tracleer, a drug for pulmonary arterial hypertension, accounts for 87 percent of Actelion’s sales and starts to lose patent protection in 2016.